All In Biotech

Drug Trial Radar · NCT06393712

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

210

Actual

Start

May 17, 2024

Primary completion

Aug 9, 2027

Study completion Dec 14, 2029

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
May 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.

Conditions

  • Cerebral Amyloid Angiopathy

Interventions

  • PlaceboDrug

    Placebo will be administered intrathecally

  • ALN-APPDrug

    ALN-APP will be administered intrathecally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double-blind Treatment Period: Annualized Rate of New Lobar Cerebral Microbleeds (CMBs) Assessed on Magnetic Resonance Imaging (MRI) of Brain in Patients with Sporadic Cerebral Amyloid Angiopathy (sCAA)Time frame: Up to 24 months

Locations

57 sites in 6 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    Orange, California

  • Clinical Trial Site

    Palo Alto, California

  • Clinical Trial Site

    Sacramento, California

  • Clinical Trial Site

    San Francisco, California

  • Clinical Trial Site

    Aurora, Colorado

  • Clinical Trial Site

    New Haven, Connecticut

  • Clinical Trial Site

    Gainesville, Florida

  • Clinical Trial Site

    Jacksonville, Florida

  • Clinical Trial Site

    Maitland, Florida

  • Clinical Trial Site

    Naples, Florida

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Lexington, Kentucky

  • Clinical Trial Site

    New Orleans, Louisiana

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Plymouth, Massachusetts

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    St Louis, Missouri

  • Clinical Trial Site

    Hackensack, New Jersey

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Durham, North Carolina

  • Clinical Trial Site

    Canton, Ohio

  • Clinical Trial Site

    Cleveland, Ohio

  • Clinical Trial Site

    Abington, Pennsylvania

  • Clinical Trial Site

    Philadelphia, Pennsylvania

  • Clinical Trial Site

    Pittsburgh, Pennsylvania

  • Clinical Trial Site

    Dallas, Texas

  • Clinical Trial Site

    Dallas, Texas

  • Clinical Trial Site

    Houston, Texas

  • Clinical Trial Site

    San Antonio, Texas

  • Clinical Trial Site

    Seattle, Washington

  • Clinical Trial Site

    Adelaide, Australia

  • Clinical Trial Site

    Brisbane, Australia

  • Clinical Trial Site

    Heidelberg, Australia

  • Clinical Trial Site

    Nedlands, Australia

  • Clinical Trial Site

    Parkville, Australia

  • Clinical Trial Site

    Calgary, Canada

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.